Eli Lilly and Company (NYSE:LLY) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On July 30, the company announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study, demonstrating that participants treated with Kisunla (donanemab-azbt) showcased slowing of decline, a benefit which continued to grow over 3 years as compared to an untreated external cohort from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). The participants showed meaningful outcomes, strengthening the long-term value of early intervention.
To provide a brief background, the TRAILBLAZER-ALZ 2 LTE study was a Phase 3, double-blind extension of the original TRAILBLAZER-ALZ 2 trial, assessing the efficacy and safety of Kisunla in individuals having early symptomatic Alzheimer’s disease. The participants who were originally treated with Kisunla either continued the treatment or were switched to a placebo. Notably, the ones initially on placebo began Kisunla in a blinded manner.
Eli Lilly and Company (NYSE:LLY) also highlighted that an earlier initiation of Kisunla reduced the risk of progression to the next stage of disease by 27% on Clinical Dementia Rating-Global Score (CDR-G). Notably, in Q2 2025, Eli Lilly and Company (NYSE:LLY)’s net income and EPS came in at $5.66 billion and $6.29, respectively, as compared to the net income of $2.97 billion and EPS of $3.28 in Q2 2024. Furthermore, the EPS in Q2 2025 and Q2 2024 both included acquired IPR&D charges of $0.14. RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its Q2 2025 investor letter. Here is what the fund said:
“Eli Lilly and Company (NYSE:LLY): LLY shares declined during the quarter despite strong top-line growth, as the company missed earnings expectations and faced heightened scrutiny around GLP-1 pricing dynamics. In Q2, Mounjaro sales rose sharply to $3.8 billion and Zepbound reached $2.3 billion in revenue. However, EPS came in below consensus due to lower pricing and temporary supply disruptions.
Source link
